A single-patient compassionate-use case in NEJM shows NTR-441 rapidly cleared SLE symptoms caused by congenital DNASE1L3 deficiency.

A peer-reviewed study found IGeneX's FDA-cleared IB tests detected early Lyme disease in 58.3% of cases versus 30.0% with standard

The European Commission has approved once-daily oral semaglutide 25 mg for weight management, making Wegovy the first GLP-1 pill available across all EU

Phase 1a data showed oral RT-114 achieved more than 150% bioavailability relative to a matched subcutaneous dose, with a mild adverse-event profile.

Sinopia's SB-0110 reduced levodopa-induced dyskinesia while boosting motor benefit in primate models, with first-in-human studies targeted for 2027.

The DP World-owned brain health facility will offer optional neurological assessments to professional boxers competing in sanctioned UAE events.

RWS has combined COA licensing, translation, linguistic validation and rater training under one programme team to cut delays in global clinical trials.

Lithuanian virologist Dr Gytis Dudas has named over a dozen newly discovered RNA viruses after Baltic mythology, folklore and even a heavy metal band.

Black Book ranked 20 NHS EPR consultants across 620 executive inputs, with KPMG UK/EPR Alliance topping the 18-criterion scorecard at 9.57.

Two-year follow-up from the VNS-REHAB trial shows durable upper-limb motor gains in 76% of participants, published in Neurology.

Phase 3 data published in STTT show orelabrutinib delivered a hazard ratio of 0.32 versus chemoimmunotherapy in treatment-naive CLL/SLL patients.

ORIC has dosed first patients in its 600-person global Phase 3 trial of rinzimetostat plus darolutamide, backed by a supply deal with Bayer.